Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, Leerink Partners Analyst Says

Xeris Biopharma (NASDAQ:XERS - Get Free Report) had its target price raised by analysts at Leerink Partners from $5.00 to $6.00 in a research report issued on Friday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Leerink Partners' target price would indicate a potential upside of 31.58% from the company's previous close.

Several other brokerages have also issued reports on XERS. HC Wainwright restated a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum boosted their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a research report on Friday, March 7th. Jefferies Financial Group reaffirmed a "buy" rating and issued a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Finally, Piper Sandler reissued a "neutral" rating and set a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $5.92.

Xeris Biopharma Stock Down 0.2 %

NASDAQ:XERS traded down $0.01 on Friday, hitting $4.56. The stock had a trading volume of 2,559,176 shares, compared to its average volume of 2,129,183. The business's 50-day simple moving average is $3.64 and its two-hundred day simple moving average is $3.29. The stock has a market cap of $679.81 million, a price-to-earnings ratio of -10.13 and a beta of 2.32. Xeris Biopharma has a 52-week low of $1.69 and a 52-week high of $4.68.

Remove Ads

Institutional Trading of Xeris Biopharma

Institutional investors have recently made changes to their positions in the business. Walleye Capital LLC purchased a new position in Xeris Biopharma during the third quarter valued at $3,197,000. JPMorgan Chase & Co. lifted its stake in Xeris Biopharma by 166.2% in the 4th quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock worth $3,537,000 after purchasing an additional 651,481 shares in the last quarter. Driehaus Capital Management LLC bought a new position in shares of Xeris Biopharma during the 4th quarter valued at about $2,014,000. Millennium Management LLC increased its holdings in shares of Xeris Biopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock worth $6,606,000 after purchasing an additional 502,853 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Xeris Biopharma by 31.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company's stock worth $7,115,000 after purchasing an additional 500,120 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.